US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aspire Biopharma Holdings Inc.

1.43

+0.12009.16%

Post-market: 1.40-0.0300-2.10%16:57 EST

Volume:467.60K

Turnover:652.57K

Market Cap:4.95M

PE:-0.02

High:1.50

Open:1.29

Low:1.29

Close:1.31

52wk High:562.80

52wk Low:1.20

Shares:3.46M

Float Shares:3.08M

Volume Ratio:0.22

T/O Rate:15.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-65.9600

EPS(LYR):-0.1190

ROE:--

ROA:-195.11%

PB:-0.43

PE(LYR):-12.01

Loading ...

Overview Company News Filings

Aspire Biopharma Appoints Phillip Balatsos to Board of Directors

Aspire Biopharma files patent application for sublingual ondansetron formulation

Aspire Biopharma Raises $21 Million in Private Placement

Aspire Biopharma Amends Bylaws to Designate Series A Preferred Stock

Buzz Bomb Caffeine Company Showcases Sublingual Supplement at Sports Nutrition Summit

Aspire Biopharma Subsidiary Buzz Bomb Signs Distribution Agreement with Blue Shark Beverages

Aspire Biopharma Holdings Announces Private Placement of Shares

Aspire Biopharma Signs Development Agreement with Microsize for Sublingual Aspirin

Aspire Biopharma files patent application for sublingual alprazolam formulation

Aspire Biopharma Holdings Inc trading halted, news pending

Aspire Biopharma Announces 1-for-40 Reverse Stock Split

Aspire Biopharma Director Surendra Ajjarapu Resigns

Aspire Biopharma Advances High-Dose Sublingual Aspirin to FDA-Supported Clinical Trial

Aspire Biopharma Swaps $1.75 Million Debt for Common Stock

Aspire Biopharma Transfers Listing to Nasdaq Capital Market After Extension Granted

Aspire Biopharma Reports Q3 2025 Update and Advances Sublingual Drug Delivery Programs

BRIEF-Aspire Biopharma Holdings Files For Offering Of Up To 41.5 Million Shares By Selling Shareholder - SEC Filing

Aspire Biopharma Holdings Inc Files for Offering of up to 41.5 Mln Shares by Selling Shareholder - SEC Filing

THOMSON REUTERS

Aspire Biopharma Submits Pre-IND Meeting Request to FDA for Sublingual Aspirin Product

Aspire Biopharma Holdings Adds Dr. Mark J. Jaroszeski to Scientific Team

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ASBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","market":"US","secType":"STK","nameCN":"Aspire Biopharma Holdings Inc.","latestPrice":1.43,"timestamp":1771016400000,"preClose":1.31,"halted":0,"volume":467598,"hourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.43,"latestTime":"16:57 EST","volume":2240,"amount":3155.689824,"timestamp":1771019871345,"change":-0.03,"changeRate":-0.020979,"amplitude":0.062937},"delay":0,"changeRate":0.0916030534351144,"floatShares":3075000,"shares":3461152,"eps":-65.96,"marketStatus":"Post-Mkt","change":0.12,"latestTime":"02-13 17:06:44 EST","open":1.29,"high":1.5,"low":1.2857,"amount":652567.6580117999,"amplitude":0.163588,"askPrice":1.4,"askSize":296,"bidPrice":1.28,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-65.96,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771030800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.31,"preHourTrading":{"tag":"盘前","latestPrice":1.3096,"preClose":1.31,"latestTime":"09:27 EST","volume":44271,"amount":56282.9574609,"timestamp":1770992870857,"change":-0.0004,"changeRate":-0.000305,"amplitude":0.092061},"postHourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.43,"latestTime":"16:57 EST","volume":2240,"amount":3155.689824,"timestamp":1771019871345,"change":-0.03,"changeRate":-0.020979,"amplitude":0.062937},"volumeRatio":0.215065},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","floatShares":3075000,"roa":"-195.11%","roe":"--","lyrEps":-0.11904,"volumeRatio":0.215065,"shares":3461152,"dividePrice":0,"high":1.5,"amplitude":0.163588,"preClose":1.31,"low":1.2857,"week52Low":1.2,"pbRate":"-0.43","psRate":"2549.95","week52High":562.8,"institutionHeld":0,"latestPrice":1.43,"committee":0.149425,"eps":-65.96,"divideRate":0,"volume":467598,"delay":0,"ttmEps":-65.96,"open":1.29,"prevYearClose":5.276,"prevWeekClose":1.46,"prevMonthClose":2.13,"prevQuarterClose":5.276,"fiveDayClose":1.46,"twentyDayClose":2.076,"sixtyDayClose":3.652},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-16","symbol":"ASBP","defaultRemindTime":1768573800000,"type":"split","dateTimestamp":1768539600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASBP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASBP","date":"2026-02-12","current":-0.02168,"percent":0.995816,"low":-107.647863,"twenty":-24.136086,"median":-0.995532,"eighty":-0.528625,"high":-0.172685,"avg":-9.797862,"sd":18.144054,"marketCap":3627354},"quantilePoints":[{"date":"2025-03-07","current":-61.718107,"twenty":-79.515888,"median":-61.718107,"eighty":-58.474317,"marketCap":40003023},{"date":"2025-03-14","current":-41.62384,"twenty":-63.871064,"median":-57.344015,"eighty":-54.828644,"marketCap":26978783},{"date":"2025-03-21","current":-49.388839,"twenty":-61.718107,"median":-55.259235,"eighty":-45.464716,"marketCap":32011722},{"date":"2025-03-28","current":-47.36506,"twenty":-59.766092,"median":-48.376949,"eighty":-45.613987,"marketCap":30699995},{"date":"2025-04-04","current":-38.75323,"twenty":-56.183571,"median":-46.367595,"eighty":-43.647619,"marketCap":25118177},{"date":"2025-04-11","current":-38.035578,"twenty":-55.34679,"median":-45.929755,"eighty":-40.946376,"marketCap":24653026},{"date":"2025-04-17","current":-39.57853,"twenty":-55.287942,"median":-45.474044,"eighty":-39.546954,"marketCap":25653101},{"date":"2025-04-25","current":-36.428037,"twenty":-53.967461,"median":-44.487272,"eighty":-38.006872,"marketCap":23611087},{"date":"2025-05-02","current":-25.763721,"twenty":-50.875815,"median":-42.879731,"eighty":-36.06634,"marketCap":16698936},{"date":"2025-05-09","current":-24.070062,"twenty":-48.174572,"median":-41.62384,"eighty":-32.456117,"marketCap":15601179},{"date":"2025-05-16","current":-8.64997,"twenty":-47.360753,"median":-40.170558,"eighty":-27.896584,"marketCap":11330354},{"date":"2025-05-23","current":-0.643502,"twenty":-46.76371,"median":-38.75323,"eighty":-25.110657,"marketCap":10952545},{"date":"2025-05-30","current":-1.730761,"twenty":-46.192459,"median":-37.963813,"eighty":-23.557658,"marketCap":29457944},{"date":"2025-06-06","current":-0.976857,"twenty":-45.929755,"median":-36.514155,"eighty":-4.677726,"marketCap":16626329},{"date":"2025-06-13","current":-1.091781,"twenty":-45.929755,"median":-34.956848,"eighty":-1.13913,"marketCap":18582368},{"date":"2025-06-20","current":-0.913361,"twenty":-45.88526,"median":-32.509654,"eighty":-1.103849,"marketCap":15545618},{"date":"2025-06-27","current":-0.879171,"twenty":-45.613987,"median":-30.966702,"eighty":-1.056614,"marketCap":14963696},{"date":"2025-07-03","current":-0.838948,"twenty":-45.240807,"median":-27.672677,"eighty":-0.926003,"marketCap":14279083},{"date":"2025-07-11","current":-0.994957,"twenty":-44.49445,"median":-25.763721,"eighty":-0.89957,"marketCap":16934405},{"date":"2025-07-18","current":-1.022827,"twenty":-44.487272,"median":-24.235121,"eighty":-0.913361,"marketCap":17408745},{"date":"2025-07-25","current":-1.492005,"twenty":-43.705031,"median":-23.47441,"eighty":-0.913361,"marketCap":25394273},{"date":"2025-08-01","current":-1.094942,"twenty":-43.417971,"median":-12.855253,"eighty":-0.926003,"marketCap":18636159},{"date":"2025-08-08","current":-0.957894,"twenty":-42.341491,"median":-1.730761,"eighty":-0.926003,"marketCap":16303583},{"date":"2025-08-15","current":-1.119076,"twenty":-41.810429,"median":-1.408829,"eighty":-0.936633,"marketCap":19046927},{"date":"2025-08-22","current":-1.407348,"twenty":-41.62384,"median":-1.381965,"eighty":-0.948126,"marketCap":26605351},{"date":"2025-08-29","current":-1.458172,"twenty":-41.494663,"median":-1.401585,"eighty":-0.950712,"marketCap":27566154},{"date":"2025-09-05","current":-1.427258,"twenty":-40.909001,"median":-1.428961,"eighty":-0.956458,"marketCap":26981748},{"date":"2025-09-12","current":-1.182832,"twenty":-39.815341,"median":-1.395821,"eighty":-0.96387,"marketCap":22360975},{"date":"2025-09-19","current":-1.153491,"twenty":-39.515377,"median":-1.375367,"eighty":-0.974558,"marketCap":21806284},{"date":"2025-09-26","current":-0.990278,"twenty":-38.902502,"median":-1.341067,"eighty":-0.987594,"marketCap":18720816},{"date":"2025-10-03","current":-1.100309,"twenty":-38.179108,"median":-1.232741,"eighty":-0.956458,"marketCap":20800907},{"date":"2025-10-10","current":-0.881819,"twenty":-37.978166,"median":-1.192915,"eighty":-0.950195,"marketCap":16670441},{"date":"2025-10-17","current":-0.836759,"twenty":-37.504515,"median":-1.176427,"eighty":-0.934507,"marketCap":15818594},{"date":"2025-10-24","current":-0.880247,"twenty":-36.758157,"median":-1.164494,"eighty":-0.913361,"marketCap":16640725},{"date":"2025-10-31","current":-0.986087,"twenty":-36.462484,"median":-1.14993,"eighty":-0.912711,"marketCap":18641575},{"date":"2025-11-07","current":-0.694243,"twenty":-35.704643,"median":-1.134878,"eighty":-0.909799,"marketCap":13124382},{"date":"2025-11-14","current":-0.275601,"twenty":-35.070237,"median":-1.124309,"eighty":-0.898954,"marketCap":5210132},{"date":"2025-11-21","current":-0.235902,"twenty":-33.9751,"median":-1.119076,"eighty":-0.881505,"marketCap":4838687},{"date":"2025-11-28","current":-0.553115,"twenty":-32.997658,"median":-1.106147,"eighty":-0.854611,"marketCap":11360337},{"date":"2025-12-05","current":-0.481425,"twenty":-32.429349,"median":-1.100309,"eighty":-0.832214,"marketCap":9887900},{"date":"2025-12-12","current":-0.546836,"twenty":-31.853289,"median":-1.093218,"eighty":-0.820326,"marketCap":11231365},{"date":"2025-12-19","current":-0.524858,"twenty":-30.859054,"median":-1.081231,"eighty":-0.778555,"marketCap":10779960},{"date":"2025-12-26","current":-0.507589,"twenty":-29.773963,"median":-1.072669,"eighty":-0.702707,"marketCap":10425286},{"date":"2026-01-02","current":-0.690217,"twenty":-28.344399,"median":-1.050409,"eighty":-0.690255,"marketCap":14176239},{"date":"2026-01-09","current":-0.540556,"twenty":-26.497162,"median":-1.035468,"eighty":-0.662273,"marketCap":11102392},{"date":"2026-01-16","current":-0.271586,"twenty":-26.171348,"median":-1.031821,"eighty":-0.631908,"marketCap":5578064},{"date":"2026-01-23","current":-0.236788,"twenty":-25.763721,"median":-1.0257,"eighty":-0.565151,"marketCap":4863341},{"date":"2026-01-30","current":-0.191,"twenty":-25.584308,"median":-1.01392,"eighty":-0.553115,"marketCap":3922916},{"date":"2026-02-06","current":-0.172685,"twenty":-24.400181,"median":-1.00377,"eighty":-0.544219,"marketCap":3546746},{"date":"2026-02-12","current":-0.17661,"twenty":-24.136086,"median":-0.995532,"eighty":-0.528625,"marketCap":3627354}],"updateTime":1771020404188},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611152445","title":"Aspire Biopharma Appoints Phillip Balatsos to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2611152445","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611152445?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:01","pubTimestamp":1770987678,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has appointed Phillip Balatsos to its Board of Directors, effective February 6, 2026. Balatsos, who brings experience from global financial institutions and board roles at other companies, will also serve on the Audit and Compensation Committees. This appointment follows the departures of Suren Ajjarapu and Donald G. Fell from the board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on February 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL735jqB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2610921054","title":"Aspire Biopharma files patent application for sublingual ondansetron formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2610921054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610921054?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:38","pubTimestamp":1770903529,"startTime":"0","endTime":"0","summary":"Aspire Biopharma (ASBP) Holdings announced the filing of a provisional patent application with the United States Patent and Trademark Office. The a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-patent-application-for-sublingual-ondansetron-formulation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-patent-application-for-sublingual-ondansetron-formulation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2610371399","title":"Aspire Biopharma Raises $21 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2610371399","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610371399?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:51","pubTimestamp":1770814262,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc.  has announced a $21 million private placement through a securities purchase agreement with select institutional and accredited investors. The agreement, signed on February 6, 2026, involves the purchase and sale of up to 26,250 shares. This move is aimed at strengthening the company’s balance sheet, enhancing its capital position, and fortifying shareholder equity to meet Nasdaq requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLc4cR6q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2609051291","title":"Aspire Biopharma Amends Bylaws to Designate Series A Preferred Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2609051291","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609051291?lang=en_us&edition=fundamental","pubTime":"2026-02-07 06:26","pubTimestamp":1770416779,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has amended its bylaws to designate 25,000 shares of Series A Convertible Preferred Stock, detailing terms such as conversion rights, limited voting rights, liquidation preferences, participation rights in future financings, and price protection provisions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL59f970:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2609308887","title":"Buzz Bomb Caffeine Company Showcases Sublingual Supplement at Sports Nutrition Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2609308887","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609308887?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:00","pubTimestamp":1770296453,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc.  operates through its wholly owned subsidiary, Buzz Bomb Caffeine Company. Buzz Bomb Caffeine Company markets BUZZ BOMB, a proprietary sublingual caffeine supplement designed for rapid absorption and convenience. The subsidiary recently launched a redesigned website and updated product branding, and is set to showcase its flagship product at The Sports & Active Nutrition Summit USA in San Diego.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL141NP8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2608387983","title":"Aspire Biopharma Subsidiary Buzz Bomb Signs Distribution Agreement with Blue Shark Beverages","url":"https://stock-news.laohu8.com/highlight/detail?id=2608387983","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608387983?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123617,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc., through its wholly owned subsidiary Buzz Bomb Caffeine Company, has entered into a strategic brand management and distribution agreement with Blue Shark Beverages. The agreement, effective February 1, 2026, is intended to expand the retail distribution of BUZZ BOMB, a 50mg sublingual caffeine stick pack, in key Southern California markets. The product rollout will begin in Palm Springs and the Coachella Valley, with a phased expansion into the Los Angeles and San Diego metropolitan areas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on February 03, 2026, and is solely responsible for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLZn5LL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2607024749","title":"Aspire Biopharma Holdings Announces Private Placement of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2607024749","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607024749?lang=en_us&edition=fundamental","pubTime":"2026-01-31 06:06","pubTimestamp":1769810792,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced an unregistered sale of equity securities through a private placement, as disclosed in a recent filing. Further details regarding the terms and size of the offering were referenced in Item 1.01 of the filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL7Gsf7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2607087678","title":"Aspire Biopharma Signs Development Agreement with Microsize for Sublingual Aspirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2607087678","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607087678?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:00","pubTimestamp":1769691654,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced an agreement with Microsize, a contract development and manufacturing organization specializing in particle size engineering for the pharmaceutical industry. Under the agreement, Microsize will support the development of Aspire's sublingual aspirin product by providing expertise in micronization and solubility enhancement. This collaboration aims to optimize the drug product for an upcoming clinical trial and support the planned submission of a New Drug Application for Aspire's 162 mg sublingual aspirin for the emergency treatment of suspected acute myocardial infarction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL8CPG5x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2604116201","title":"Aspire Biopharma files patent application for sublingual alprazolam formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116201","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116201?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:56","pubTimestamp":1768917373,"startTime":"0","endTime":"0","summary":"Aspire Biopharma (ASBP) Holdings announced the filing of a new provisional patent application with the United States Patent and Trademark Office. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-patent-application-for-sublingual-alprazolam-formulation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-patent-application-for-sublingual-alprazolam-formulation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2603937660","title":"Aspire Biopharma Holdings Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937660","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603937660?lang=en_us&edition=fundamental","pubTime":"2026-01-16 08:50","pubTimestamp":1768524610,"startTime":"0","endTime":"0","summary":"19:50 EST Aspire Biopharma (ASBP) Holdings Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-holdings-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-holdings-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2603616141","title":"Aspire Biopharma Announces 1-for-40 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616141","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616141?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:05","pubTimestamp":1768395930,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a 1-for-40 reverse stock split of its common stock, effective January 16, 2026. The company's shares will begin trading on a split-adjusted basis under the same Nasdaq ticker symbol, ASBP, with a new CUSIP number 738920 206.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on January 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL8Mt6T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2603658178","title":"Aspire Biopharma Director Surendra Ajjarapu Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2603658178","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603658178?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:31","pubTimestamp":1768339873,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. announced that Surendra Ajjarapu has resigned from his position as Director, effective immediately. The company stated that his departure was not due to any disagreement with the board or management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLFmrw7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2601803153","title":"Aspire Biopharma Advances High-Dose Sublingual Aspirin to FDA-Supported Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601803153","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601803153?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:01","pubTimestamp":1767790864,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a successful Type B pre-Investigational New Drug  meeting with the U.S. Food and Drug Administration  regarding its investigational product, acetylsalicylic acid 162 mg sublingual powder , intended for the emergency treatment of suspected acute myocardial infarction. The FDA provided feedback supporting a 505 regulatory filing targeted for the second half of 2026 and indicated that no additional studies are required beyond the currently planned 32-subject clinical trial. Initial evaluations of OTASA have indicated that the product was safe and well-tolerated with no reported adverse events. Results from the planned clinical trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL6Yfqgl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2601890949","title":"Aspire Biopharma Swaps $1.75 Million Debt for Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890949?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:36","pubTimestamp":1767706574,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has entered into Exchange Agreements with certain holders of its debt to convert approximately $1.75 million in outstanding debt into shares of the company's common stock. The debt originated from agreements made by the company's predecessor, PowerUp Acquisition Corp., in early 2024. The transaction involves accredited investors and relies on exemptions from registration under the Securities Act. Additionally, the agreements provide that, upon future financings exceeding $3 million, holders may elect to receive a portion of the proceeds in cash to repay outstanding balances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL1bBwv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2591268463","title":"Aspire Biopharma Transfers Listing to Nasdaq Capital Market After Extension Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2591268463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591268463?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:00","pubTimestamp":1765576828,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. announced it will transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the opening of business on December 15, 2025. The company's shares will continue to trade under the symbol \"ASBP,\" and trading will remain unaffected by the transfer. Aspire has been granted an extension by the Nasdaq Hearings Panel to meet certain conditions related to its continued listing, with key deadlines set for early 2026. The company is taking steps to address these requirements and aims to position itself for long-term shareholder value.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to genera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2GN9K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2588887475","title":"Aspire Biopharma Reports Q3 2025 Update and Advances Sublingual Drug Delivery Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887475","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887475?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:00","pubTimestamp":1764856818,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc.  provided a business update for the quarter ended September 30, 2025. During the third quarter, the company expanded its scientific team with the addition of Dr. Mark J. Jaroszeski, a tenured professor from the University of South Florida, to support development of its sublingual drug delivery technology. Aspire reported progress on its sublingual ED medication program, with plans to finalize formulation and manufacture a test product in the first half of 2026, and to begin a Phase 1 pharmacokinetic clinical cross-over study by mid-2026. The company highlighted the clinical validation of its technology with sublingual aspirin and noted a targeted New Drug Application  submission for this product in the first half of 2026. Aspire also pointed to continued commercial execution with Buzz Bomb Caffeine Company's second production order of two million servings of BUZZ BOMB. In addition, Aspire filed an omnibus patent application with the U.S. Patent and Tradem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL1zvN4v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2588466450","title":"BRIEF-Aspire Biopharma Holdings Files For Offering Of Up To 41.5 Million Shares By Selling Shareholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588466450","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588466450?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:49","pubTimestamp":1764766158,"startTime":"0","endTime":"0","summary":"BRIEF-Aspire Biopharma Holdings Files For Offering Of Up To 41.5 Million Shares By Selling Shareholder - SEC FilingDec 3  - Aspire Biopharma Holdings Inc ASBP.O:ASPIRE BIOPHARMA HOLDINGS INC FILES FOR OFFERING OF UP TO 41.5 MILLION SHARES BY SELLING SHAREHOLDER - SEC FILINGSource text: [ID:n0001493152-25-025819]Further company coverage: ASBP.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X817I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2588010011","title":"Aspire Biopharma Holdings Inc Files for Offering of up to 41.5 Mln Shares by Selling Shareholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588010011","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588010011?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:05","pubTimestamp":1764759952,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X817I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2588056295","title":"Aspire Biopharma Submits Pre-IND Meeting Request to FDA for Sublingual Aspirin Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056295","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056295?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:00","pubTimestamp":1764684026,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has submitted a Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration  for its lead product candidate, a fast-acting, high-dose sublingual aspirin formulation intended for the treatment of suspected acute myocardial infarction . This submission marks an important step in seeking FDA guidance on the clinical development strategy and confirmation of the proposed 505 regulatory pathway. No grant or funding involving Aspire or multiple organizations is mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 02, 2025, and is solely responsible for the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7LMyND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2586250219","title":"Aspire Biopharma Holdings Adds Dr. Mark J. Jaroszeski to Scientific Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250219","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250219?lang=en_us&edition=fundamental","pubTime":"2025-11-26 22:00","pubTimestamp":1764165631,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced the addition of Dr. Mark J. Jaroszeski to its scientific team. Dr. Jaroszeski joins as a new member and is a tenured professor in the Department of Medical Engineering at the University of South Florida.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL2Tg3sp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}